ahlam1399
09-18-2015, 12:02 AM
BRIEF-Advaxis says therapy improves survival rates in cervical cancer patients
* Says Axalimogene Filolisbac showed 38.5 percent 12-month survival in patients with persistent/recurrent metastatic cervical cancer http://feeds.feedburner.com/~ff/reuters/governmentfilingsNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/governmentfilingsNews?a=GHdjGKiGxd4:HUJMbjyKJsU:yI l2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/governmentfilingsNews?i=GHdjGKiGxd4:HUJMbjyKJsU:V_ sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/governmentfilingsNews?a=GHdjGKiGxd4:HUJMbjyKJsU:V_ sGLiPBpWU) http://feeds.feedburner.com/~ff/reuters/governmentfilingsNews?i=GHdjGKiGxd4:HUJMbjyKJsU:F7 zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/governmentfilingsNews?a=GHdjGKiGxd4:HUJMbjyKJsU:F7 zBnMyn0Lo)
http://feeds.feedburner.com/~r/reuters/governmentfilingsNews/~4/GHdjGKiGxd4
* Says Axalimogene Filolisbac showed 38.5 percent 12-month survival in patients with persistent/recurrent metastatic cervical cancer http://feeds.feedburner.com/~ff/reuters/governmentfilingsNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/governmentfilingsNews?a=GHdjGKiGxd4:HUJMbjyKJsU:yI l2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/governmentfilingsNews?i=GHdjGKiGxd4:HUJMbjyKJsU:V_ sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/governmentfilingsNews?a=GHdjGKiGxd4:HUJMbjyKJsU:V_ sGLiPBpWU) http://feeds.feedburner.com/~ff/reuters/governmentfilingsNews?i=GHdjGKiGxd4:HUJMbjyKJsU:F7 zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/governmentfilingsNews?a=GHdjGKiGxd4:HUJMbjyKJsU:F7 zBnMyn0Lo)
http://feeds.feedburner.com/~r/reuters/governmentfilingsNews/~4/GHdjGKiGxd4